Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 180
Summary
- Conditions
- Advanced Solid Tumors
- Biliary Tract Cancers
- Colorectal Cancer
- Gastric Cancer
- Glioblastoma
- Ovarian Cancer
- Pancreatic Cancer
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03797326
- Collaborators
- Eisai Inc.
- Investigators
- Study Director: Medical Director Merck Sharp & Dohme Corp.